Terms: = Lung cancer AND EML4, ENSG00000143924, 27436 AND Prognosis
60 results:
1. Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce lung cancer Regrowth after Crizotinib Treatment.
Horvat NK; Chocarro S; Marques O; Bauer TA; Qiu R; Diaz-Jimenez A; Helm B; Chen Y; Sawall S; Sparla R; Su L; Klingmüller U; Barz M; Hentze MW; Sotillo R; Muckenthaler MU
ACS Nano; 2024 Apr; 18(17):11025-11041. PubMed ID: 38626916
[TBL] [Abstract] [Full Text] [Related]
2. Longitudinal plasma proteomic profiling of eml4-ALK positive lung cancer receiving ALK-TKIs therapy.
Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
[TBL] [Abstract] [Full Text] [Related]
3. lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-eml4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing.
Zhang S; Dong P; Pan Z; Chen Q; Zhu J; Mao Z
Med Oncol; 2023 Nov; 40(12):349. PubMed ID: 37935925
[TBL] [Abstract] [Full Text] [Related]
5. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
6. Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of lung Adenocarcinoma.
Kulda V; Polivka J; Svaton M; Vanecek T; Buresova M; Houfkova K; Bagheri MS; Knizkova T; Vankova B; Windrichova J; Macan P; Babuska V; Pesta M
Cancer Genomics Proteomics; 2023; 20(4):404-411. PubMed ID: 37400146
[TBL] [Abstract] [Full Text] [Related]
7. eml4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract] [Full Text] [Related]
8. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell lung cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract] [Full Text] [Related]
9. The Change in Paradigm for NSCLC Patients with eml4-ALK Translocation.
Bearz A; De Carlo E; Del Conte A; Spina M; Da Ros V; Bertoli E; Revelant A; Stanzione B; Tirelli U
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806325
[TBL] [Abstract] [Full Text] [Related]
10. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
[TBL] [Abstract] [Full Text] [Related]
11. [Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and pathological analysis].
Di SH; Wang XT; Xia QY; Lu ZF; Ma HH; Zhang RS; Wang X; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):28-32. PubMed ID: 34979750
[No Abstract] [Full Text] [Related]
12. The impact of the
Wang S; Luo R; Shi Y; Han X
Future Oncol; 2022 Jan; 18(3):385-402. PubMed ID: 34783600
[No Abstract] [Full Text] [Related]
13. Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study.
Jiang F; Wang C; Yang P; Sun P; Liu J
World J Surg Oncol; 2021 Sep; 19(1):278. PubMed ID: 34530849
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological, Radiological, and Molecular Features of Primary lung Adenocarcinoma with Morule-Like Components.
Wang LL; Ding L; Zhao P; Guan JJ; Ji XB; Zhou XL; Shao SH; Zou YW; Fu WW; Lin DL
Dis Markers; 2021; 2021():9186056. PubMed ID: 34234879
[TBL] [Abstract] [Full Text] [Related]
15. Coexistence of a secondary STRN-ALK, eml4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract] [Full Text] [Related]
16. Treatment of Brain Metastases of Non-Small Cell lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract] [Full Text] [Related]
17. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell lung cancer.
Kauffmann-Guerrero D; Kahnert K; Huber RM
Drugs; 2021 Jan; 81(1):87-100. PubMed ID: 33226527
[TBL] [Abstract] [Full Text] [Related]
18. [Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell lung cancer].
Wang S; Shi Y; Han X
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):1014-1022. PubMed ID: 33203201
[TBL] [Abstract] [Full Text] [Related]
19. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
[TBL] [Abstract] [Full Text] [Related]
20. Distribution of eml4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Tao H; Shi L; Zhou A; Li H; Gai F; Huang Z; Che N; Liu Z
Lung Cancer; 2020 Nov; 149():154-161. PubMed ID: 33017727
[TBL] [Abstract] [Full Text] [Related]
[Next]